3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Weight Loss
1
Preleukemia
1
Ovarian Neoplasms
1
Osteochondroma
1
Obesity
1
Non-alcoholic Fatty Liver Disease
1
Nevus, Epithelioid and Spindle Cell
1
Myelodysplastic Syndromes
1
Malnutrition
1
Lung Neoplasms
1
Hematologic Neoplasms
1
Glioblastoma
1
Giant Cell Tumors
1
Gastrointestinal Neoplasms
1
Fibrosis
1
Esophageal Squamous Cell Carcinoma
1
Endometrial Neoplasms
1
Endometrial Hyperplasia
1
Carcinoma, Merkel Cell
1
Carcinoma, Lobular
1
Carcinoma in Situ
1
Barrett Esophagus
1
Interventions
Cyclophosphamide
184
fludarabine phosphate
162
fludarabine
128
Busulfan
116
Tacrolimus
109
Mycophenolic Acid
101
Whole-Body Irradiation
97
Antilymphocyte Serum
87
Peripheral Blood Stem Cell Transplantation
84
Azacitidine
82
Melphalan
81
Filgrastim
74
Cytarabine
74
Cyclosporine
72
Methotrexate
64
Decitabine
57
Granulocyte Colony-Stimulating Factor
51
Thiotepa
45
Radiotherapy
41
thymoglobulin
40
Stem Cell Transplantation
40
Cord Blood Stem Cell Transplantation
40
venetoclax
39
Clofarabine
35
Sirolimus
30
Methylprednisolone
30
Specimen Handling
27
Etoposide
24
Alemtuzumab
24
Biopsy
23
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Myelodysplastic Syndromes
×
Sampling Studies
×
Clear all
NCT02809222
2021-04-19
PLASMYC
University Hospital, Tours
Phase NA
Completed
138 enrolled